Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

A Home Run for Pembrolizumab plus Chemotherapy Combination in Newly Diagnosed Metastatic Non–Small-Cell Lung Cancer

TOP - August 2018, Vol 11, No 2 - Lung Cancer
Phoebe Starr

 

A burning question is whether immunotherapy combinations will further improve outcomes compared with checkpoint inhibitor therapy alone—and if so, which combinations will rise to the top. Combining pembrolizumab (Key­truda) with standard pemetrexed (Alimta) plus a platinum-based chemotherapy improved overall survival (OS) versus chemotherapy alone as first-line therapy for patients with metastatic nonsquamous non–small-cell lung cancer (NSCLC) in KEYNOTE-189, a phase 3 clinical trial. The survival benefit with pembroliz­umab plus chemotherapy was independent of PD-L1 expression.

These results were published online (Gandhi L, et al. N Engl J Med. 2018;378: 2078-2092) the day they were presented at the 2018 American Association for Cancer Research meeting, and made the front page of The New York Times.

“Halving the risk of death is an unprecedented effect of therapy in the first-line setting for advanced nonsquamous NSCLC without EGFR or ALK alterations,” stated lead investigator Leena Gandhi, MD, PhD, Director, Thoracic Medical Oncology Program, Perlmutter Cancer Center, NYU Langone Health, New York City.

“In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembroliz­umab to standard chemotherapy with pemetrexed and a platinum-based drug resulted in significantly longer OS and progression-free survival [PFS] than chemotherapy alone. Pembrolizu­mab plus pemetrexed and platinum may be a new standard of care for first-line treatment of metastatic nonsquamous NSCLC, irrespective of PD-L1 expression,” Dr Gandhi told listeners.

The KEYNOTE-189 Study

KEYNOTE-189 enrolled 616 patients with untreated stage IV nonsquamous NSCLC and no sensitizing EGFR or ALK alterations. Patients were stratified for PD-L1 expression (tumor proportion score <1% or ≥1%) and randomized in a 2:1 ratio to treatment with 4 cycles of pembrolizumab plus pemetrexed and carboplatin or cisplatin or to placebo plus these chemotherapies. In the experimental arm, maintenance therapy was pembrolizumab plus pemetrexed; in the placebo arm, maintenance therapy was pemetrexed. Patients were allowed to cross over to pembrolizumab alone if they had disease progression.

A significant benefit in OS was observed with pembrolizumab plus chemotherapy. The median OS was not yet reached in the experimental arm versus 11.3 months in the control arm. At 12 months, 69.2% of patients were alive in the experimental arm versus 49.4% in the control arm, a significant improvement in OS (P <.0001).

All subgroups benefited from the addition of pembrolizumab, but the greatest benefit was in the high PD-L1 expression (≥50%) group.

The PFS was significantly improved in the pembrolizumab arm, with a median PFS of 8.8 months versus 4.9 months for the controls, representing a 51% improvement. The 1-year PFS was 34.1% versus 17.3%, respectively (P <.0001). The PFS benefit was greatest in the group with high PD-L1 expression, but other subgroups also fared better with pembrolizumab than without.

Safety Analysis

The rate of adverse events was similar across both treatment arms. Almost every patient had at least 1 adverse event, and approximately 67% had a grade ≥3 adverse event.

The rate of treatment discontinuation because of adverse events was 13.8% in the pembrolizumab combination arm versus 7.9% in the control arm.

Immune-mediated adverse events were 22.7% in the pembrolizumab arm versus 11.9% in the placebo arm. Grade ≥3 acute renal injury was more common with the pembro­lizumab combination, 5.2% versus 0.5% in the control arm; grade 3/4 nephritis was reported in 1.5% versus 0%, respectively.

Dr Gandhi said that although all subgroups had a survival benefit with pembrolizumab, PD-L1 testing is still needed.

“We would be hesitant to give up on that biomarker. PD-L1 may be part of a biomarker, perhaps added to tumor mutational burden,” Dr Gandhi stated.

“In the US, we routinely get PD-L1 testing for most nonsquamous NSCLC. We also typically order next-generation sequencing, which can estimate tumor mutational burden,” she added.

During the discussion, Roy S. Herbst, MD, MS, PhD, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT, stated that this new triplet combination will change the standard of care.

“The answer to the question about whether these results will change the standard of care for untreated nonsquamous NSCLC is an absolute ‘Yes,’” he emphasized. “This randomized phase 3 trial sets a new standard. The results of this trial quite frankly exceeded expectations. The study showed extraordinary rates of OS, PFS, and objective response.”

Related Items
Zepzelca New Therapy Approved for Metastatic Small-Cell Lung Cancer
Web Exclusives published on June 22, 2020 in FDA Updates, Lung Cancer
FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation
Web Exclusives published on June 8, 2020 in FDA Updates, Lung Cancer
Opdivo plus Yervoy and Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression
Web Exclusives published on June 2, 2020 in FDA Updates, Lung Cancer
Tecentriq Approved as First-Line Therapy for Metastatic NSCLC with High PD-L1 Expression
Web Exclusives published on May 26, 2020 in FDA Updates, Lung Cancer
Sitravatinib, Novel TKI, plus Nivolumab Elicits Good Responses in Renal-Cell Carcinoma
Phoebe Starr
TOP - May 2020, Vol 13, No 3 published on May 21, 2020 in Emerging Therapies
First-in-Class Oral MK-6482 Shows Exciting Results in Clear-Cell Renal-Cell Carcinoma
Phoebe Starr
TOP - May 2020, Vol 13, No 3 published on May 21, 2020 in Emerging Therapies
Opdivo-Yervoy First Immunotherapy Combo Approved for First-Line Therapy of Patients with Metastatic NSCLC
Web Exclusives published on May 18, 2020 in FDA Updates, Lung Cancer
Real-World Healthcare Utilization and Costs Support Broader Use of CAR T-Cell Therapy
Phoebe Starr
TOP - March 2020, Vol 13, No 2 published on March 11, 2020 in Value-Based Care
Mosunetuzumab, a Dual-Targeted Antibody, Shows Complete Remissions in Relapsed/Refractory NHL After CAR T-Cell Therapy By
Phoebe Starr
TOP - March 2020, Vol 13, No 2 published on March 11, 2020 in ASH 2019 Highlights
Improving Access to Genetic Cancer Screening in a Medically Underserved Community
Phoebe Starr
TOP - March 2020, Vol 13, No 2 published on March 11, 2020 in ACCC
Last modified: April 27, 2020